really don't get why arql participating. waste of time unless something significant to announce which we all know is not the case. I can't say I'm optimistic about crc...seems like they are not either...barely a mention on last call.
Any company has to do presentations at investor-banker conferences. For ARQL, it is vital to carry a message that they have recovered for the Marquee panic/paralysis and intend to develop their pipeline.
As for mCRC, let us wait and see. It is a Double Blind trial with pts living more than 2 years.
Chan leaving. I do hope this isn't beginning of management exodus. If Arql was a start up, investors would be excited to have a company with a drug going into ph3 in major indication, followed by several significant ph2 trials in progress, about to file a new IND, a solid cash position and experienced management team...(at least they are now!). Would seem like attractive buyout candidate but big pharma will only buy "success" and we don't have that here...yet.